Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to -$4.0 million.

  • Cellebrite DI's Capital Expenditures fell 2448.08% to -$4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$13.2 million, marking a year-over-year decrease of 5438.94%. This contributed to the annual value of -$13.2 million for FY2025, which is 5438.94% down from last year.
  • Cellebrite DI's Capital Expenditures amounted to -$4.0 million in Q4 2025, which was down 2448.08% from -$3.3 million recorded in Q3 2025.
  • Cellebrite DI's 5-year Capital Expenditures high stood at $749000.0 for Q4 2021, and its period low was -$4.0 million during Q4 2025.
  • For the 5-year period, Cellebrite DI's Capital Expenditures averaged around -$1.4 million, with its median value being -$1.2 million (2022).
  • Per our database at Business Quant, Cellebrite DI's Capital Expenditures surged by 102469.14% in 2021 and then tumbled by 146962.03% in 2023.
  • Cellebrite DI's Capital Expenditures (Quarter) stood at $749000.0 in 2021, then crashed by 285.71% to -$1.4 million in 2022, then tumbled by 62.47% to -$2.3 million in 2023, then tumbled by 40.62% to -$3.2 million in 2024, then dropped by 24.48% to -$4.0 million in 2025.
  • Its Capital Expenditures stands at -$4.0 million for Q4 2025, versus -$3.3 million for Q3 2025 and -$3.6 million for Q2 2025.